Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

First-of-Its-Kind Diabetic Retinopathy Treatment Approved Roche’s Susvimo is now the first and only FDA-approved continuous ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Results of a phase IIb trial comparing UBX1325 to anti-VEGF therapy are expected later this year. A single intravitreal injection of UBX1325 (foselutoclax), a novel senolytic small molecule ...

In this Healio Video Perspective from the Retina World Congress, Baruch D. Kuppermann, MD, PhD, shares positive data on the dexamethasone intravitreal implant for diabetic macular edema. The ...

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) today announced that it obtained regulatory approval from the Ministry ...